The stock of Cybin Inc (AMEX:CYBN) last traded at $0.62, up 12.32% from the previous session.
Data from the available sources indicates that Cybin Inc (AMEX:CYBN) is covered by 4 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $4.50. Given the previous closing price of $0.55, this indicates a potential upside of 718.18 percent. CYBN stock price is now 39.57% away from the 50-day moving average and 57.88% away from the 200-day moving average. The market capitalization of the company currently stands at $148.55M.
In total, 0 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
A total of 16.25% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc shares was purchased by INTEROCEAN CAPITAL GROUP, LLC during the first quarter worth $62,000. CONNECTICUT WEALTH MANAGEMENT, LLC invested $33,000 in shares of CYBN during the first quarter. In the first quarter, THRIVE WEALTH MANAGEMENT, LLC acquired a new stake in Cybin Inc valued at approximately $33,000. LPL FINANCIAL LLC acquired a new stake in CYBN for approximately $17,000. LEGACY FINANCIAL GROUP LLC purchased a new stake in CYBN valued at around $14,000 in the second quarter. In total, there are 72 active investors with 11.03% ownership of the company’s stock.
With an opening price of $0.5600 on Friday morning, Cybin Inc (AMEX: CYBN) set off the trading day. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.71. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.61, and a quick ratio of 2.61. The fifty day moving average price for CYBN is $0.4493 and a two-hundred day moving average price translates $0.3926 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Jun, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
